Pfizer In Divestiture Talks Over $68B Wyeth Merger

Law360, New York (March 18, 2009, 12:00 AM EDT) -- Pfizer Inc. may be required to divest parts of its animal health businesses before regulators approve its $68 billion acquisition of Wyeth Inc., a deal detractors claim creates problematic overlaps in the pharmaceutical giants' products.

On Wednesday, Pfizer CFO Frank D’Amelio reportedly took the floor at an investor conference in Boston, saying Pfizer is discussing possible divestitures with the Federal Trade Commission. Joan Campion, a spokeswoman for Pfizer, confirmed the statement.

While regulators are investigating the full gamut of products involved in the proposed merger, both...
To view the full article, register now.